RESEARCH ARTICLE

ALCOHOL
CLINICAL & EXPERIMENTAL RESEARCH

Impact of alcohol use disorder severity on human immunodeficiency virus (HIV) viral suppression and CD4 count in three international cohorts of people with HIV

Nicolas Bertholet[1] | Richard Saitz[2,3] | Judith A. Hahn[4,5] | Timothy C. Heeren[6] | Nneka I. Emenyonu[5] | Matthew Freiberg[7] | Michael R. Winter[8] | Theresa W. Kim[2] | Kara M. Magane[3] | Christine Lloyd-Travaglini[8] | Robin Fatch[5] | Kendall Bryant[9] | Leah S. Forman[8] | Lindsey Rateau[8] | Elena Blokhina[10] | Winnie R. Muyindike[11] | Natalia Gnatienko[2] | Jeffrey H. Samet[2]

[1]Department of Psychiatry, Addiction Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

[2]Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA

[3]Department of Community Health Sciences, Boston University School of Public Health, Boston, Massachusetts, USA

[4]Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA

[5]Department of Medicine, University of California San Francisco, San Francisco, California, USA

[6]Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA

[7]Vanderbilt Center for Clinical Cardiovascular Trials Evaluation (V-C3REATE), Vanderbilt University Medical Center, Cardiovascular Division, Nashville, Tennessee, USA

[8]Biostatistics and Epidemiology Data Analytics Center (BEDAC), Boston University School of Public Health, Boston, Massachusetts, USA

[9]HIV/AIDS Research, National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA

[10]First Pavlov State Medical University of Saint Petersburg, St. Petersburg, Russia

[11]Department of Internal Medicine, Mbarara University of Science and Technology, Mbarara, Uganda

Correspondence
Nicolas Bertholet, Department of Psychiatry, Addiction Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Email: Nicolas.Bertholet@chuv.ch

Abstract

Background: Alcohol use has been linked to worse human immunodeficiency virus (HIV) immunologic/virologic outcomes, yet few studies have explored the effects of alcohol use disorder (AUD). This study assessed whether AUD severity is associated with HIV viral suppression and CD4 count in the three cohorts of the Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium.

Methods: People with HIV (PWH) in Uganda ($n = 301$), Russia ($n = 400$), and Boston ($n = 251$), selected in-part based on their alcohol use, were included in analyses. Logistic and linear regressions were used to assess the cross-sectional associations between AUD severity (number of DSM-5 diagnostic criteria) and (1) HIV viral suppression, and (2) CD4 count (cells/mm^3) adjusting for covariates. Analyses were conducted separately by site.

Results: The proportion of females was 51% (Uganda), 34% (Russia), and 33% (Boston); mean age (SD) was 40.7 (9.6), 38.6 (6.3), and 52.1 (10.5), respectively. All participants in Uganda and all but 27% in Russia and 5% in Boston were on antiretroviral therapy. In Uganda, 32% met criteria for AUD, 92% in Russia, and 43% in Boston. The mean (SD) number of AUD criteria was 1.6 (2.4) in Uganda, 5.6 (3.3) in Russia, and 2.4 (3.1) in Boston. Most participants had HIV viral suppression (Uganda 92%, Russia 57%, Boston 87%); median (IQR) CD4 count was 673 (506, 866), 351 (201, 542), and 591 (387, 881), respectively. In adjusted models, there were no associations between AUD severity and HIV viral suppression: adjusted odds ratios (AOR) (95%CI) per 1 additional AUD criterion in Uganda was 1.08 (0.87, 1.33); Russia 0.98 (0.92, 1.04); and Boston 0.95 (0.84, 1.08) or CD4 count: mean difference (95%CI) per 1 additional criterion: 5.78 (−7.47, 19.03), −3.23 (−10.91, 4.44), and −8.18 (−24.72, 8.35), respectively.

Conclusions: In three cohorts of PWH, AUD severity was not associated with HIV viral suppression or CD4 count. PWH with AUD in the current era of antiretroviral therapy can achieve virologic control.

KEYWORDS
alcohol use disorder, CD4, HIV, viral suppression

INTRODUCTION

Among people with HIV (PWH), unhealthy alcohol use is common, with a quarter reporting heavy episodic drinking in the USA (Williams et al., 2017). Alcohol use is an important aspect of HIV clinical care and prevention (Boscarino et al., 1995; Freeman, 2016; Parsons et al., 2008; Shuper et al., 2017) and has been associated with HIV seroconversion. In addition, the negative effect of alcohol on HIV disease progression is attributed to its impact on indirect processes such as reduced linkage to HIV care, delayed initiation of antiretroviral therapy (ART), worse treatment retention, and lower ART adherence (Chander et al., 2006; Lucas et al., 2002; Williams et al., 2016). Studies suggest there is a dose–response relationship between greater alcohol use and ART nonadherence (Braithwaite et al., 2005; Chander et al., 2006; Hahn & Samet, 2010; Hendershot et al., 2009; Williams et al., 2018). However, there is conflicting evidence on the degree to which alcohol use affects HIV outcomes via other mechanisms, such as the biological effect of alcohol itself on the immune system and nutritional deficiencies (Hahn et al., 2018; Hahn & Samet, 2010). In a systematic review and meta-analysis, Rehm and colleagues concluded that, except for the link mediated by ART nonadherence, the contribution of other pathways from alcohol to HIV burden of disease could not be quantified given current knowledge (Rehm et al., 2017).

Alcohol use disorder (AUD) is a condition characterized by impaired control over drinking and physical and emotional symptoms related to continued use despite negative consequences. Accordingly, diagnostic criteria for AUD focus on the consequences of use, without reference to the volume of alcohol consumption. As a result, the quantity and frequency of alcohol use varies widely among those with AUD. Consequences of use as reflected in diagnostic criteria

may have a different association and mechanism of association with HIV outcomes than the quantity of alcohol use per se. Whether alcohol's impact on HIV outcomes is due to its disruptive effect on social and behavioral functioning as reflected by AUD diagnostic criteria—rather than direct effects of the volume of alcohol consumption itself on immunological and viral outcomes—has different implications for improving HIV outcomes among PWH who drink alcohol.

Alcohol use disorder is common worldwide among PWH. In a meta-analysis of 25 studies, the pooled prevalence of alcohol use disorder measured mostly by the AUDIT scale was 30%. The prevalence was even higher when analyses were limited to developed countries (Duko et al., 2019). Among PWH with either past 12-month alcohol and/or other drug dependence, the number of criteria met for the diagnosis, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) fourth edition (IV), was associated with detectable HIV viral load (Nolan et al., 2017) in a multivariable model that included number of DSM-IV alcohol dependence criteria and other measures of alcohol and other drug use. This suggests that social and behavioral effects of a substance use disorder as quantified by number of DSM criteria rather than nondependent substance use are important.

Alcohol use disorder is a prevalent condition among PWH and one that could impact HIV disease progression with both direct biological effects and indirect effects on social, behavioral, and emotional dysregulation on medication adherence and treatment retention. The current study assessed the cross-sectional associations between AUD severity and HIV outcomes, specifically viral suppression and CD4 count, among PWH in three cohorts from different continents. We studied these internationally diverse cohorts because, in addition to quantifying alcohol exposure by the volume of alcohol consumption, the effects of alcohol may depend on and

differ by sociocultural context, which may be more accurately quantified by the number of AUD symptoms (or DSM diagnostic criteria). The study hypotheses were that a greater number of AUD criteria would be associated with lower odds of viral suppression and lower CD4 count in three separate study cohorts. The study was conducted in the Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) Consortium. URBAN ARCH allows for evaluating the association between AUD and HIV outcomes in multiple cohorts from different geographic and socio-economic backgrounds.

MATERIALS AND METHODS

Study design

This cross-sectional study used baseline data from three cohorts from URBAN ARCH. PWH from Uganda ($n = 301$), Russia ($n = 400$), and Boston ($n = 251$) were included. Uganda ARCH was conducted in Mbarara, Uganda, Russia ARCH in St. Petersburg, Russia, and Boston ARCH in Boston, USA.

Participants, overview

The study population consisted of PWH with various levels of alcohol and other substance use, including abstinence. All participants provided informed consent. Assessments were conducted in-person by trained research personnel.

Uganda ARCH cohort

The Uganda participants were enrolled in the ADEPTT study (Alcohol Drinker's Exposure to Preventive Therapy for Tuberculosis, NCT 03302299), whose aim was to compare the safety and tolerability of tuberculosis preventive therapy in PWH with recent alcohol use (any use in past 3 months, $n = 201$) compared to those with no alcohol use in the past year ($n = 100$). Inclusion criteria included: age ≥ 18 years, fluency in English or Runyankole, HIV-infection on a nonnevirapine containing antiretroviral therapy (ART) regimen for at least 6 months, liver function tests (alanine aminotransferase and aspartate aminotransferase) <2 times the upper limit of normal, and living within 2 h travel time from the Immune Suppression Syndrome (ISS) clinic of the Mbarara Regional Referral Hospital with no plans to move. Data for the present study were baseline visits, collected from May 2017 to January 2020.

Russia ARCH cohort

The Russia participants were enrolled in the St. PETER HIV study (Studying Partial agonists for EtOH and Tobacco Elimination in Russians with HIV study) whose aim was to test the efficacy of varenicline, cytisine, and nicotine replacement therapy for heavy alcohol use and tobacco use (Tindle et al., 2020). Inclusion criteria included: age 18–70 years old, HIV-infected, fluency in Russian, reporting daily tobacco use, >5 heavy drinking days over the past 30 days, provision of contact information for two contacts to assist with follow-up, stable address within St. Petersburg or districts within 100 kilometers of St. Petersburg, and possession of a home or mobile phone. Data for the present study were collected from July 2017 to December 2019.

Boston ARCH cohort

The Boston participants were enrolled in a study on alcohol use and falls. Inclusion criteria included: age ≥18 years, HIV-infection, and at least one of the following: any illicit drug use in the past 12 months, unhealthy alcohol use (AUDIT-C score >3 for women, >4 for men) or enrollment in a previous Boston ARCH study (Kim et al., 2018). Other criteria were fluency in English, willingness to provide contact information for at least one person, and no plans to move from the area within the next year. Participants were recruited in-person from a hospital-based HIV primary care clinic. Data for the present study were collected from February 2018 to March 2020.

Outcomes

The study outcomes were HIV viral suppression and CD4 cell count. The definition of HIV viral suppression was cohort-specific based on local laboratory standards and was defined as <40 copies/mL in the Uganda cohort, <300 copies/mL in the Russia cohort, and <200 copies/mL in the Boston cohort. As these thresholds were used in the different cohorts, we kept the definition of HIV virologic control as defined in each cohort. CD4 cell count was examined as a continuous variable (in cells/mm^3). CD4 count and HIV viral load were collected by electronic health record review in the Boston ARCH cohort and phlebotomy in the Russia ARCH and Uganda ARCH cohorts.

Main independent variable

The main independent variable was the number of alcohol use disorder criteria (AUD) according to the DSM-5 (range 0–11; American Psychiatric Association, 2013) based on survey items measuring the DSM criteria. The number of AUD criteria was used as a proxy for AUD severity. AUD data were collected the same way in each cohort. Each DSM-5 AUD criterion was assessed in standardized structured interviews with a set of 11 questions based upon the MINI and AUDADIS questionnaires (American Psychiatric Association, 2013; Grant et al., 1995; Sheehan et al., 1998) resulting in a score between 0 and 11. There were minor wording differences due to the different cultural backgrounds and languages.

Covariates

Covariates were selected based on the literature. Factors considered as potential confounders included sex, age, marital status (dichotomous, defined in Uganda as having a spouse, in Russia and Boston as being married or living with a partner), basic education level (defined in Uganda and Russia >9 grades vs. less and Boston as high school graduate or more vs. less), employment status (currently employed or not), current (past 30 day use) of illicit opioids, cannabis, stimulants (amphetamines and/or cocaine), and tobacco.

The opioid, cannabis, and stimulant use covariates were included in the analyses of the Russia and Boston cohorts only (because it was rare in the Uganda cohort: 0% opioid and stimulant use, 0.7% cannabis use). The tobacco use covariate was included for Uganda and Boston cohorts only (because tobacco use was 100% in the Russia cohort, as it was part of study inclusion criteria).

The Uganda, Russia, and Boston ARCH cohorts all have individual level data. Nevertheless, covariates differed by cohort and could not be pooled into a single analysis without risking substantial bias, and because the relevant covariates differed by cohort, one might expect with cohorts from different parts of the world.

Logistic and linear regression models were used to assess the associations between each additional AUD criterion and HIV viral suppression and CD4 count, respectively. To attempt to separate out the effect of AUD severity from volume of drinking, additional models were conducted adjusting for volume of alcohol use (total grams of alcohol in the past 30 days calculated with a 14-day Timeline Followback for the Boston cohort and a 30-day Timeline Followback for the Uganda and Russia cohorts). These models were used as a sensitivity analysis but not as the primary analysis because we expected the volume of alcohol use to be strongly correlated with AUD severity. We used the same analytic strategy to test the association of AUD severity and viral suppression and CD4 count only among those with an AUD (i.e., at least 2 AUD DSM-5 criteria) rather than the entire sample.

Russia ARCH was approved by the institutional review board (IRB) of Boston University Medical Campus, First St. Petersburg Pavlov State Medical University, and Vanderbilt University Medical Center. Uganda ARCH was approved by the IRB of Boston University Medical Campus, University of California, San Francisco, Mbarara University of Science and Technology, and the Uganda National Council of Science and Technology. Boston ARCH was approved by the IRB of Boston University Medical Campus.

RESULTS

The proportion of females was 51% (Uganda), 34% (Russia), and 33% (Boston); the mean age (SD) was 40.7 (9.6), 38.6 (6.3), and 52.1 (10.5), respectively. All but 27.3% in Russia and 5.2% in Boston were on ART (in the Uganda cohort being on ART was an inclusion criterion). The mean (Standard Deviation [SD]) number of AUD criteria was 1.6 (2.4) in Uganda, 5.6 (3.3) in Russia, and 2.4 (3.1) in Boston. Viral suppression was achieved in 92% of the sample in Uganda, 57% in Russia, and 87% in Boston; median (IQR) CD4 count was 673 (506, 866), 351 (201, 542), and 591 (387, 881), respectively. The sample characteristics, by cohort, are presented in Table 1. The prevalence of HIV virologic suppression and CD4 count differed across cohorts with the Russia cohort having the lowest prevalence of HIV viral suppression at 57% and the lowest mean CD4 cell count.

Associations between AUD severity and HIV outcomes

In unadjusted models, there were no significant associations between the number of AUD criteria and either HIV viral suppression or CD4 count in the three cohorts. Similarly, in adjusted models, there was no significant cross-sectional association between the number of AUD criteria and HIV viral suppression: AOR (95%CI) per 1 additional AUD criterion in Uganda 1.08 (0.87, 1.33); Russia 0.98 (0.92, 1.04); and Boston 0.95 (0.84, 1.08) or CD4 count: beta (mean difference) (95%CI) per 1 additional criterion: 5.78 (−7.47, 19.03), −3.23 (−10.91, 4.44), and −8.18 (−24.72, 8.35), respectively. Detailed results of the regression models are presented in Tables 2 and 3. Correlations between volume of alcohol use (grams of EtOH) and number of AUD criteria were 0.70 in Uganda, 0.45 in Russia, and 0.60 in Boston; despite these high correlations, adjusting for the volume of alcohol used did not change the results (Table 4). In the analyses restricted to those with an AUD, results were similar (Table 5).

DISCUSSION

Using data from three cohorts from different continents allowed us to examine of the relationship between AUD severity, as reflected by number of diagnostic criteria, and HIV outcomes in populations with vastly different socio-economic and cultural backgrounds and health care systems. The results were consistent in three cohorts of PWH, from Uganda, Russia, and the USA, and contrary to our hypothesis, we did not detect any associations between AUD severity and HIV viral suppression or CD4 counts. Our results indicate that PWH and AUD can achieve virologic control and suggest that AUD severity—as measured by DSM criteria—is not associated with HIV viral suppression and CD4 count. AUD did not appear to impact these two outcomes significantly in our cohorts of PWH, most of whom were receiving ART. The observed measures of effect are close to 1 for the ORs of virologic suppression and the slopes for CD4 count are close to zero in all cohorts. Taking the volume of alcohol use into account did not change the results. Restricting analyses to those with an AUD did not either. This consistent absence of association across cohorts and different analyses reinforces these results.

By examining cohorts separately, we attempted to minimize the variability in access to ART one might expect in different countries, the effect of which could overwhelm any impact of AUD on viral

TABLE 1 Participant characteristics of the Uganda, Russia, and Boston HIV+ cohorts.

	Uganda (n = 301)	Russia (n = 400)	Boston (n = 251)
Gender			
Male, n (%)	147 (48.8%)	263 (65.8%)	169 (67.3%)
Female, n (%)	154 (51.2%)	137 (34.3%)	82 (32.7%)
Age, mean (SD)	40.7 (9.6)	38.6 (6.3)	52.1 (10.5)
Married or living with partner, n (%)	202 (67.3%)	197 (49.3%)	129 (51.6%)
Basic education[a], n (%)	81 (26.9%)	390 (97.5%)	190 (75.7%)
Employed, n (%)	289 (96.0%)	260 (65.0%)	62 (24.7%)
Any illicit opioid use, 30 days, n (%)	0 (0.0%)	97 (24.3%)	40 (15.9%)
Any cannabis use, 30 days, n (%)	2 (0.7%)	46 (11.5%)	125 (49.8%)
Any stimulant use, 30 days, n (%)	0 (0.0%)	21 (5.3%)	70 (27.9%)
Any tobacco use, 30 days, n (%)	35 (11.6%)	400 (100.0%)	157 (62.8%)
ART adherence[c]			
Not on ART, n (%)	—[b]	109 (27.3%)	13 (5.2%)
<90% adherence, n (%)	43 (14.3%)	24 (6.0%)	62 (24.8%)
≥90% adherence, n (%)	258 (85.7%)	267 (66.8%)	175 (70.0%)
HIV viral suppression[d], n (%)	269 (92.1%)	228 (57.0%)	208 (86.7%)
CD4 count (in cells/mm^3), mean (SD)	706.2 (287.2)	391.3 (256.5)	664.0 (375.1)
Alcohol use disorder score (# of criteria), mean (SD)	1.6 (2.4)	5.6 (3.3)	2.4 (3.1)
Alcohol use disorder (2 or more criteria), n (%)	96 (32.0%)	366 (91.5%)	106 (42.6%)
Total grams of alcohol, 30 days[e], mean (SD)	296.8 (926.7)	1018.8 (829.0)	525.7 (911.6)
Number of heavy drinking days, 30 days[e], mean (SD)	1.4 (4.8)	9.3 (5.8)	3.3 (6.5)

[a] Boston HS grad or more; Uganda and Russia >9 grades.

[b] Being on ART was an entry criterion for Uganda.

[c] All cohorts used a visual analog scale for self-reported adherence. Adherence was defined as taking ART on ≥90% of days in the past month.

[d] Boston <200 copies/mL; Uganda <40 copies/mL; Russia <300 copies/mL.

[e] Extrapolated from the 14-day Timeline Followback for the Boston cohort, a 30-day Timeline Followback for the Uganda and Russia cohorts.

suppression. While we did not see an association in cohorts with a spectrum of access to ART, most cohort participants were receiving ART. Accordingly, characteristics of the three samples may have played a role in these findings. Given that being on ART for 6 months or longer was a study entry criterion for the Uganda cohort, it is possible that the effects of AUD on viral suppression would be evident in other populations in Uganda with greater variability in ARV receipt because of alcohol's effect on disrupting care engagement, care-seeking, and ART prescribing. Participants enrolled in Uganda ARCH had managed to overcome those obstacles—at least enough to meet study criteria for Uganda ARCH eligibility. It is notable, therefore, that the study results were consistent in the Russia cohort who had a broader range of ART use, from no ART prescription to full (self-reported) adherence.

The results differ from what has been hypothesized on the potential impact of alcohol use disorder and alcohol use on HIV disease progression. The literature has reported on the detrimental impact of alcohol use on HIV disease progression through biological and behavioral mechanisms (Hahn & Samet, 2010). Earlier studies have shown associations between alcohol use (and any AUD) and lower engagement in HIV care and notably with ART adherence (Giordano et al., 2005; Mellins et al., 2009; Monroe et al., 2016; Samet

et al., 2003; Tucker et al., 2003). This is consistent with an effect of alcohol use on HIV viral suppression mediated by ART adherence (Amirkhanian et al., 2018; Deiss et al., 2016; Rehm et al., 2017). The assessment of this study's three cohorts revealed similarities among participants: most received ART and of those on ART, 78% or more were >=90% ART adherent. The latter may have precluded identification of an impact on HIV viral suppression. In addition, as recent research suggests, ART adherence level of 75%–80% may allow achievement of viral suppression (Byrd et al., 2019).

Our approach was aimed at investigating the potential impact of AUD and not quantity of alcohol consumption. This is important because AUD is a widely used diagnosis in clinical care. While AUD and alcohol use are correlated, our approach aimed at taking into account the behavioral aspects of AUD (e.g., loss of control over drinking, giving up activities, interference with self-care, risk behavior taking), which are potentially linked to decreased adherence to treatment, ART discontinuation, and HIV care drop-out (Azar et al., 2010). Thus, our results are not directly comparable to studies assessing the impact of alcohol volume on HIV outcomes.

Research findings have been mixed when investigating the associations between alcohol use and HIV outcomes. Our results are in line with a parent cohort study of ART naïve participants in

TABLE 2 HIV viral suppression: Unadjusted and adjusted logistic regressions, associations with the number of AUD criteria.[a]

Unadjusted models	Uganda, n = 291		Russia, n = 400		Boston, n = 238	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value	OR (95% CI)	p-Value
AUD criteria (per 1 additional criterion)	1.03 (0.86, 1.24)	0.76	0.97 (0.91, 1.03)	0.26	0.90 (0.81, 1.01)	0.07
Adjusted models	**Uganda, n = 291**		**Russia, n = 400**		**Boston, n = 238**	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value	OR (95% CI)	p-Value
AUD criteria (per 1 additional criterion)	1.08 (0.87, 1.33)	0.50	0.98 (0.92, 1.04)	0.46	0.95 (0.84, 1.08)	0.44
Sex (ref = Male)	2.36 (0.85, 6.55)	0.10	1.19 (0.76, 1.84)	0.45	0.74 (0.30, 1.82)	0.51
Age (continuous)	1.02 (0.97, 1.08)	0.35	1.03 (1.00, 1.07)	0.05	1.03 (0.99, 1.08)	0.16
Marital Status (ref = No)	0.51 (0.16, 1.62)	0.25	1.14 (0.76, 1.72)	0.53	0.83 (0.37, 1.88)	0.66
Education (ref = Less than basic)	3.02 (0.85, 10.67)	0.09	0.26 (0.05, 1.31)	0.10	0.56 (0.18, 1.72)	0.31
Employment (ref = Unemployed)	1.75 (0.20, 15.51)	0.61	1.32 (0.85, 2.04)	0.22	0.70 (0.24, 2.04)	0.51
Current illicit opioid use (ref = No)	—	—	0.77 (0.48, 1.25)	0.29	0.29 (0.11, 0.77)	0.01
Current cannabis use (ref = No)	—	—	1.08 (0.56, 2.10)	0.81	1.75 (0.71, 4.30)	0.22
Current stimulant use (ref = No)	—	—	0.75 (0.28, 1.99)	0.56	0.59 (0.23, 1.48)	0.26
Current tobacco use (ref = No)	1.16 (0.30, 4.51)	0.83	—	—	0.53 (0.19, 1.47)	0.22

[a] Uganda <40 copies/mL; Russia <300 copies/mL; Boston <200 copies/mL.

TABLE 3 Results of unadjusted and adjusted linear regressions examining associations between the number of AUD criteria and CD4 count (mean difference in cells/mm^3).

Unadjusted models	Uganda, n = 299		Russia, n = 399		Boston, n = 241	
	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value
AUD criteria (per 1 addl criterion)	−5.21 (−18.19, 7.77)	0.43	−4.03 (−11.59, 3.52)	0.29	−6.54 (−22.05, 8.98)	0.41
Adjusted models	**Uganda, n = 299**		**Russia, n = 399**		**Boston, n = 241**	
	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value
AUD criteria (per 1 addl criterion)	5.78 (−7.47, 19.03)	0.39	−3.23 (−10.91, 4.44)	0.41	−8.18 (−24.72, 8.35)	0.33
Sex (ref = Male)	192.37 (122.34, 262.39)	<0.0001	28.33 (−26.63, 83.30)	0.31	−14.96 (−122.43, 92.51)	0.78
Age	−0.71 (−3.90, 2.48)	0.66	−2.09 (−6.17, 1.99)	0.31	−3.80 (−8.97, 1.38)	0.15
Marital Status (ref = No)	15.03 (−52.42, 82.48)	0.66	42.52 (−8.56, 93.59)	0.10	13.03 (−84.75, 110.82)	0.79
Education (ref = Less than basic)	97.66 (30.20, 165.13)	0.005	−52.98 (−220.01, 114.05)	0.53	−67.03 (−185.68, 51.62)	0.27
Employment (ref = Unemployed)	20.91 (−132.24, 174.07)	0.79	1.01 (−53.96, 55.98)	0.97	18.16 (−107.86, 144.19)	0.78
Current illicit opioid use (ref = No)	—	—	−78.91 (−139.03, −18.18)	0.01	48.36 (−95.68, 192.40)	0.51
Current cannabis use (ref = No)	—	—	56.58 (−25.92, 139.08)	0.18	21.48 (−81.72, 124.68)	0.68
Current stimulant use (ref = No)	—	—	61.29 (−129.79, 111.20)	0.88	−35.22 (−157.32, 86.89)	0.57
Current tobacco use (ref = No)	2.12 (−97.14, 101.37)	0.97	—	—	−2.16 (−111.67, 107.34)	0.97

which unhealthy alcohol use was not associated with CD4 count (Hahn et al., 2018). In a cross-sectional study of PWH from southern Brazil, there was an association between a proxy measure of AUD (AUDIT score) and CD4 count but not HIV viral load (Da Silva et al., 2017). Our results differ notably from a recent study by Williams et al. showing, in a sample of PWH receiving VA healthcare, that higher levels of alcohol use were associated with a reduced likelihood of virologic control (Williams et al., 2019). The higher prevalence of viral suppression in the current study may have limited the ability to detect associations. While it has been hypothesized that the influence of alcohol use on HIV outcomes happens through reduced ART adherence, newer regimens are "more forgiving" such that adherence rates needed for viral suppression are lower compared to the regimens in earlier studies (Byrd et al., 2019; Gordon et al., 2015). Also, while we included cohorts from three different continents, the current study did not include participants from some regions where such associations have been previously shown (e.g., India and Vietnam; Wagman et al., 2020). Nonetheless, we did include Russia where the impact of alcohol on HIV outcomes has been described (Wagman et al., 2020).

Although we found AUD severity was not associated with HIV viral suppression and CD4 count, the impact of AUD and alcohol use may still be significant among people who did not meet

TABLE 4 Results of logistic and linear regressions with and without adjustment for alcohol volume and other covariates.

Associations with HIV viral suppression[a]	Uganda, n = 290		Russia, n = 400		Boston, n = 238	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Unadjusted, AUD criteria continuous (per 1 addl criterion)	1.03 (0.86, 1.24)	0.76	0.97 (0.91, 1.03)	0.26	0.90 (0.81, 1.01)	0.07
AUD criteria + total grams of alcohol (not incl. covariates)	0.99 (0.81, 1.2)	0.94	0.96 (0.90, 1.03)	0.24	0.95 (0.84, 1.09)	0.47
AUD criteria + total grams of alcohol (incl. covariates[b])	1.02 (0.82, 1.27)	0.84	0.97 (0.91, 1.04)	0.34	1.00 (0.87, 1.16)	0.97
Associations with CD4 count[c]	**Uganda, n = 298**		**Russia, n = 399**		**Boston, n = 241**	
	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value
Unadjusted, AUD criteria (per 1 addl criterion)	−5.21 (−18.19, 7.77)	0.43	−4.03 (−11.59, 3.52)	0.29	−6.54 (−22.05, 8.98)	0.41
AUD criteria + total grams of alcohol[d] (not incl. covariates)	−7.36 (−21.36, 6.65)	0.30	−2.80 (−11.08, 5.49)	0.51	−15.91 (−33.56, 1.73)	0.08
AUD criteria + total grams of alcohol (incl. covariates[b])	1.61 (−12.11, 15.33)	0.82	−2.86 (−11.17, 5.45)	0.50	−17.54 (−35.88, 0.81)	0.06

[a] Uganda <40 copies/ml; Russia <300 copies/ml; Boston <200 copies/mL.

[b] Covariates: sex, age, marital status, education level, employment, current opioid use, current cannabis use, current stimulant use, current tobacco use.

[c] Beta = mean differences in CD4 cell count.

[d] Total grams of alcohol was calculated with a 14-day Timeline Followback for the Boston cohort, a 30-day Timeline Followback for the Uganda and Russia cohorts.

TABLE 5 Analyses restricted to participants with AUD: logistic and linear regressions.

Associations with HIV viral suppression[a]	Uganda, n = 95		Russia, n = 366		Boston, n = 103	
	OR (95% CI)	p-Value	OR (95% CI)	p-Value	OR (95% CI)	p-Value
Unadjusted, AUD criteria (continuous)	1.04 (0.75, 1.44)	0.80	0.94 (0.88, 1.00)	0.06	0.91 (0.76, 1.10)	0.34
AUD criteria (adjusted for covariates[b])	1.04 (0.77, 1.40)	0.81	0.95 (0.89, 1.02)	0.13	0.97 (0.79, 1.20)	0.80
AUD criteria + total grams of alcohol[d] (not incl. covariates)	1.02 (0.74, 1.40)	0.92	0.93 (0.87, 1.00)	0.06	0.94 (0.77, 1.14)	0.52
AUD criteria (adjusted for covariates[b] + total grams alcohol)	1.03 (0.77, 1.39)	0.84	0.94 (0.87, 1.01)	0.08	1.00 (0.80, 1.26)	0.98
Associations with CD4 count[c]	**Uganda, n = 96**		**Russia, n = 365**		**Boston, n = 103**	
	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value	Beta (95% CI)	p-Value
Unadjusted, AUD criteria (continuous)	5.24 (−16.71, 27.20)	0.64	−3.53 (−11.93, 4.86)	0.41	−17.03 (−44.46, 10.40)	0.22
AUD criteria (adjusted for covariates[b])	7.52 (−14.76, 29.80)	0.50	−2.72 (−11.17, 5.74)	0.53	−18.30 (−47.82, 11.22)	0.22
AUD criteria + total grams of alcohol[d] (not incl. covariates)	2.59 (−19.61, 24.78)	0.82	−2.06 (−11.19, 7.06)	0.66	−21.37 (−48.92, 6.18)	0.13
AUD criteria (adjusted for covariates[b] + total grams alcohol)	4.84 (−16.95, 26.62)	0.66	−2.29 (−11.39, 6.81)	0.62	−23.12 (−52.42, 6.18)	0.12

[a] Uganda <40; Russia <300; Boston <200.

[b] Covariates: sex, age, marital status, education level, employment, current opioid use, current marijuana use, current stimulant use, current tobacco use.

[c] Beta = mean differences in CD4 cell count.

[d] Total grams of alcohol was extrapolated from the 14-day Timeline Followback for the Boston Cohort, 30-day Timeline Followback for the Uganda and Russia cohorts.

inclusion criteria for these cohorts and the most vulnerable fringe of the population that may not have been included in the studies. In addition, there are other ways in which alcohol use is detrimental with regard to HIV. Notably, alcohol use has been associated with poorer HIV care engagement and retention (Monroe et al., 2016; Samet et al., 1998, 2001, 2003). The current study did not allow the assessment of the impact of AUD on care initiation and timely diagnosis.

This study has limitations. While data from three different cohorts allowed for the study of populations from different backgrounds, the use of different definitions, notably for HIV viral suppression, was a limitation with comparing different cohorts. Models did not include the same covariates for each cohort due to important differences in the prevalence of illicit drug use. This study is cross-sectional in nature and thus did not allow for an examination of the effect of AUD severity on ART discontinuation and HIV care drop-out over time. In addition, causality could not be assessed due to the study's cross sectional and observational design. While we did not detect an association with each additional DSM-5 criterion, our analyses assumed that each criterion would be additive and with the same value. It may well be that certain criteria such as tolerance, for example, would have little impact on adherence, while criteria that reflect life disorganization (failure to fulfill roles) would be more impactful. It would require a larger sample and variability of meeting criteria to study this question.

The current study has notable strengths. AUD was assessed systematically for research purposes—data that would be less reliably available in clinical samples. We did not use a proxy measure of AUD (like AUDIT-C), which would be less relevant to our study hypothesis. Instead we looked at clinical symptoms of an AUD (alcohol problems/disorder) extending the current literature. In addition, we were able to use unique data with similar research instruments used in three international cohorts.

Given the high prevalence of alcohol use and AUD among PWH, further research could facilitate better understanding of how alcohol use and AUD impact clinical populations of PWH. Independent of its impact on HIV outcomes, AUD is a treatable disease that should be addressed and appropriately treated to prevent numerous complications. Our results do not indicate that AUD is not harmful for PWH.

CONCLUSIONS

In cohorts from three different continents, we assessed the association between AUD severity and HIV outcomes (i.e., viral suppression and CD4 count). Our results suggest that quantifying AUD severity by number of DSM-5 criteria is not associated with these outcomes. We observed high rates of viral suppression even among those with AUD.

CONFLICT OF INTEREST STATEMENT
No competing interests.

ORCID
Nicolas Bertholet https://orcid.org/0000-0001-5064-6377
Richard Saitz https://orcid.org/0000-0002-2535-1427
Judith A. Hahn https://orcid.org/0000-0002-2697-8264
Theresa W. Kim https://orcid.org/0000-0001-6043-0721
Jeffrey H. Samet https://orcid.org/0000-0002-0897-3400

REFERENCES

American Psychiatric Association. (2013) *Diagnostic and statistical manual of mental disorders*, 5th edition. Washington, DC: American Psychiatric Association.

Amirkhanian, Y.A., Kelly, J.A., DiFrancesico, W.J., Kuznetsova, A.V., Tarima, S.S., Yakovlev, A.A. et al. (2018) Predictors of HIV care engagement, antiretroviral medication adherence, and viral suppression among people living with HIV infection in St. Petersburg, Russia. *AIDS and Behavior*, 22(3), 791–799.

Azar, M.M., Springer, S.A., Meyer, J.P. & Altice, F.L. (2010) A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. *Drug and Alcohol Dependence*, 112(3), 178–193.

Boscarino, J.A., Avins, A.L., Woods, W.J., Lindan, C.P., Hudes, E.S. & Clark, W. (1995) Alcohol-related risk factors associated with HIV infection among patients entering alcoholism treatment: implications for prevention. *Journal of Studies on Alcohol*, 56(6), 642–653.

Braithwaite, R.S., McGinnis, K.A., Conigliaro, J., Maisto, S.A., Crystal, S., Day, N. et al. (2005) A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. *Alcoholism, Clinical and Experimental Research*, 29(7), 1190–1197.

Byrd, K.K., Hou, J.G., Hazen, R., Kirkham, H., Suzuki, S., Clay, P.G. et al. (2019) Antiretroviral adherence level necessary for HIV viral suppression using real-world data. *Journal of Acquired Immune Deficiency Syndromes*, 82(3), 245–251.

Chander, G., Lau, B. & Moore, R.D. (2006) Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. *Journal of Acquired Immune Deficiency Syndromes*, 43(4), 411–417.

Da Silva, C.M., Mendoza-Sassi, R.A., Da Mota, L.D., Nader, M.M. & De Martinez, A.M. (2017) Alcohol use disorders among people living with HIV/AIDS in southern Brazil: prevalence, risk factors and biological markers outcomes. *BMC Infectious Diseases*, 17(1), 263.

Deiss, R.G., Mesner, O., Agan, B.K., Ganesan, A., Okulicz, J.F., Bavaro, M. et al. (2016) Characterizing the association between alcohol and HIV virologic failure in a military cohort on antiretroviral therapy. *Alcoholism, Clinical and Experimental Research*, 40(3), 529–535.

Duko, B., Ayalew, M. & Ayano, G. (2019) The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. *Substance Abuse Treatment, Prevention, and Policy*, 14(1), 52.

Freeman, R.C. (2016) Toward development of enhanced preventive interventions for HIV sexual risk among alcohol-using populations: confronting the 'Mere pause from Thinking'. *AIDS and Behavior*, 20(Suppl 1), S1–S18.

Giordano, T.P., Visnegarwala, F., White, A.C., Jr., Troisi, C.L., Frankowski, R.F., Hartman, C.M. et al. (2005) Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. *AIDS Care*, 17(6), 773–783.

Gordon, L.L., Gharibian, D., Chong, K. & Chun, H. (2015) Comparison of HIV virologic failure rates between patients with variable

adherence to three antiretroviral regimen types. *AIDS Patient Care and STDs*, 29(7), 384–388.

Grant, B.F., Harford, T.C., Dawson, D.A., Chou, P.S. & Pickering, R.P. (1995) The alcohol use disorder and associated disabilities interview schedule (AUDADIS): reliability of alcohol and drug modules in a general population sample. *Drug and Alcohol Dependence*, 39(1), 37–44.

Hahn, J.A., Cheng, D.M., Emenyonu, N.I., Lloyd-Travaglini, C., Fatch, R., Shade, S.B. et al. (2018) Alcohol use and HIV disease progression in an antiretroviral naive cohort. *Journal of Acquired Immune Deficiency Syndromes*, 77(5), 492–501.

Hahn, J.A. & Samet, J.H. (2010) Alcohol and HIV disease progression: weighing the evidence. *Current HIV/AIDS Reports*, 7(4), 226–233.

Hendershot, C.S., Stoner, S.A., Pantalone, D.W. & Simoni, J.M. (2009) Alcohol use and antiretroviral adherence: review and meta-analysis. *Journal of Acquired Immune Deficiency Syndromes*, 52(2), 180–202.

Kim, T.W., Walley, A.Y., Ventura, A.S., Patts, G.J., Heeren, T.C., Lerner, G.B. et al. (2018) Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. *AIDS Care*, 30(2), 150–159.

Lucas, G.M., Gebo, K.A., Chaisson, R.E. & Moore, R.D. (2002) Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. *AIDS*, 16(5), 767–774.

Mellins, C.A., Havens, J.F., McDonnell, C., Lichtenstein, C., Uldall, K., Chesney, M. et al. (2009) Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. *AIDS Care*, 21(2), 168–177.

Monroe, A.K., Lau, B., Mugavero, M.J., Mathews, W.C., Mayer, K.H., Napravnik, S. et al. (2016) Heavy alcohol use is associated with worse retention in HIV care. *Journal of Acquired Immune Deficiency Syndromes*, 73(4), 419–425.

Nolan, S., Walley, A.Y., Heeren, T.C., Patts, G.J., Ventura, A.S., Sullivan, M.M. et al. (2017) HIV-infected individuals who use alcohol and other drugs, and virologic suppression. *AIDS Care*, 29(9), 1129–1136.

Parsons, J.T., Rosof, E. & Mustanski, B. (2008) The temporal relationship between alcohol consumption and HIV-medication adherence: a multilevel model of direct and moderating effects. *Health Psychology*, 27(5), 628–637.

Rehm, J., Probst, C., Shield, K.D. & Shuper, P.A. (2017) Does alcohol use have a causal effect on HIV incidence and disease progression? A review of the literature and a modeling strategy for quantifying the effect. *Population Health Metrics*, 15(1), 4.

Samet, J.H., Freedberg, K.A., Savetsky, J.B., Sullivan, L.M., Padmanabhan, L. & Stein, M.D. (2003) Discontinuation from HIV medical care: squandering treatment opportunities. *Journal of Health Care for the Poor and Underserved*, 14(2), 244–255.

Samet, J.H., Freedberg, K.A., Savetsky, J.B., Sullivan, L.M. & Stein, M.D. (2001) Understanding delay to medical care for HIV infection: the long-term non-presenter. *AIDS*, 15(1), 77–85.

Samet, J.H., Freedberg, K.A., Stein, M.D., Lewis, R., Savetsky, J., Sullivan, L. et al. (1998) Trillion virion delay: time from testing positive for HIV to presentation for primary care. *Archives of Internal Medicine*, 158(7), 734–740.

Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E. et al. (1998) The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *The Journal of Clinical Psychiatry*, 59(Suppl 20), 22–33; quiz 34-57.

Shuper, P.A., Joharchi, N., Monti, P.M., Loutfy, M. & Rehm, J. (2017) Acute alcohol consumption directly increases HIV transmission risk: a randomized controlled experiment. *Journal of Acquired Immune Deficiency Syndromes*, 76(5), 493–500.

Tindle, H.A., Freiberg, M.S., Gnatienko, N., Blokhina, E., Cheng, D.M., Yaroslavtseva, T. et al. (2020) Design of a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia. *Contemporary Clinical Trials Communications*, 19, 100625.

Tucker, J.S., Burnam, M.A., Sherbourne, C.D., Kung, F.Y. & Gifford, A.L. (2003) Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. *The American Journal of Medicine*, 114(7), 573–580.

Wagman, J.A., Wynn, A., Matsuzaki, M., Gnatienko, N., Metsch, L.R., Del Rio, C. et al. (2020) Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. *AIDS*, 34(15), 2285–2294.

Williams, E.C., Hahn, J.A., Saitz, R., Bryant, K., Lira, M.C. & Samet, J.H. (2016) Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. *Alcoholism, Clinical and Experimental Research*, 40(10), 2056–2072.

Williams, E.C., Joo, Y.S., Lipira, L. & Glass, J.E. (2017) Psychosocial stressors and alcohol use, severity, and treatment receipt across human immunodeficiency virus (HIV) status in a nationally representative sample of US residents. *Substance Abuse*, 38(3), 269–277.

Williams, E.C., McGinnis, K.A., Bobb, J.F., Rubinsky, A.D., Lapham, G.T., Skanderson, M. et al. (2018) Changes in alcohol use associated with changes in HIV disease severity over time: a national longitudinal study in the veterans aging cohort. *Drug and Alcohol Dependence*, 189, 21–29.

Williams, E.C., McGinnis, K.A., Edelman, E.J., Matson, T.E., Gordon, A.J., Marshall, B.D.L. et al. (2019) Level of alcohol use associated with HIV care continuum targets in a national U.S. sample of persons living with HIV receiving healthcare. *AIDS and Behavior*, 23(1), 140–151.